Ensysce Biosciences, Inc.: Ensysce Biosciences Announces Initial Patients Dosed of First Human Abuse Potential Study
~ Trial Designed to Test and Confirm Nasal Opioid Manipulation ~SAN DIEGO, CA / ACCESSWIRE / July 13, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC:ENSCW), a clinical-stage
Source: finanznachrichten.de